Clinical Trials Logo

Clinical Trial Details — Status: Suspended

Administrative data

NCT number NCT05186077
Other study ID # STUDY20201112
Secondary ID 1R56MH121598-01A
Status Suspended
Phase
First received
Last updated
Start date October 15, 2020
Est. completion date July 31, 2024

Study information

Verified date October 2023
Source Case Western Reserve University
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The goal of this cross-sectional study is to use diffusion-weighted imaging based tractography (DWT) to assess white matter (WM) pathways in treatment-refractory bipolar disorder (REF-BD) and treatment responsive bipolar disorder (RSP-BD) subjects compared to healthy controls (HCs). This project will include a prospective controlled trial to include 50 subjects with REF-BD, 50 patients RSP-BD and 50 healthy volunteers.


Recruitment information / eligibility

Status Suspended
Enrollment 42
Est. completion date July 31, 2024
Est. primary completion date July 31, 2024
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility Group 1: Healthy Volunteers Inclusion Criteria for Group 1: 1. Male or female =18 years of age 2. Capable of understanding/complying with protocol requirements 3. Has competency to understand and sign informed consent form 4. Physically healthy with no acute medical condition and =3 stable, chronic medical conditions 5. Without current and/or lifetime psychiatric disorders as assessed by the Mini International Neuropsychiatric Interview for DSM-5 (MINI) Exclusion Criteria for Group 1: 1. Acute medical condition or >3 stable, chronic health conditions 2. Significant structural brain lesion 3. Progressive neurological disease 4. Preexisting implanted electrical device 5. Currently pregnant or planning to become pregnant 6. Contraindications to MR imaging 7. Tests positive for cannabis, illegal substances, or prescription medications without valid prescription 8. Currently taking steroids, opioids, or other agents that might affect brain circuitry per research team discretion 9. Use of cigarettes or other nicotine products within 12 hours of imaging visit 10. Use of stimulants 24 hours prior MRI visit 11. Presents an immediate danger to self or others as judged by research psychiatrist 12. Has psychiatric disorder, including alcohol/drug use disorder or personality disorder Group 2: Treatment-Responsive BDI Inclusion Criteria for Group 2: 1. Male or female =18 years of age 2. Capable of understanding/complying with protocol requirements 3. Has competency to understand and sign informed consent form 4. Physically healthy with no acute medical condition and =3 stable, chronic medical conditions 5. Meets diagnostic criteria for BDI or BDII according to the DSM-5 criteria 6. Must be stable on current BD medications with no dosing changes in the last 30 days or not currently taking any BD medications. 7. Recent mood episode must currently be in remission for > 8 weeks 8. Montgomery-Asberg Depression Rating Scale (MADRS) =10 total score during the psychiatric assessments portion and at the MRI visit (if repeated at MRI visit) 9. Young Mania Rating Scale (YMRS) =12 total score during the psychiatric assessments portion and at the MRI visit (if repeated at MRI visit) 10. Clinical Global Impression-Severity for Bipolar Disorder (CGI-S-BD) =2 during the psychiatric assessments visit 11. Must be adherent (= 80%) with BD medication(s) Exclusion Criteria for Group 2: 1. Acute medical condition or >3 stable, chronic health conditions 2. Significant structural brain lesion 3. Progressive neurological disease 4. Preexisting implanted electrical device 5. Currently pregnant or planning to become pregnant 6. Contraindications to MR imaging 7. Tests positive for cannabis, illegal substances, or prescription medications without valid prescription 8. Currently taking steroids, opioids, or other agents that might affect brain circuitry per research team discretion 9. Use of cigarettes or other nicotine products within 12 hours of imaging visit 10. Use of stimulants within 24 hours of imaging visit 11. Presents an immediate danger to self or others as judged by research psychiatrist 12. Has had changes in medications within 30 days 13. Contribution of any co-occurring psychiatric comorbidity disproportionate to contribution of BDI or BDII 14. Meets DSM-5 criteria for current borderline or antisocial personality disorder 15. Meets DSM-5 criteria for alcohol and/or drug use disorder within 6 months, excluding caffeine and/or nicotine Group 3: Treatment-Refractory BDI Inclusion Criteria for Group 3: 1. Male or female =18 years of age 2. Capable of understanding/complying with protocol requirements 3. Has competency to understand and sign informed consent form 4. Physically healthy with no acute medical condition and =3 stable, chronic medical conditions 5. Meets diagnostic criteria for BDI or BDII according to the DSM-5 criteria 6. Must be stable on drugs, including at least 1 mood stabilizer, with no dosing changes in the last 30 days 7. GCI-S-BD >3 at the psychiatric assessments visit 8. MADRS =20 total score or YMRS =18 total score during the psychiatric assessments portion and at the MRI visit (if repeated at MRI visit) 9. BD-associated mood episodes are primary source of disability, according to both subject and psychiatrist 10. Current depressive episode lasting =6 months despite = 2 adequate evidence-based first-line treatment > 8 weeks, current manic/hypomanic episode lasting =2 months despite = 2 adequate evidence-based first-line treatment > 4 weeks, or meeting rapid cycling criteria in last 12 months despite =2 evidence-based first-line treatments for BDI or BDII assessed with assistance of Modified Antidepressant Treatment History Form (MATHF) 11. Severe impairment with score of =7 on at least one of three subscales of Sheehan Disability Scale (SDS), which includes assessment of work-life, family-life, and social life during the psychiatric assessments portion Exclusion Criteria for Group 3: 1. Acute medical condition or >3 stable, chronic health conditions 2. Significant structural brain lesion 3. Progressive neurological disease 4. Preexisting implanted electrical device 5. Currently pregnant or planning to become pregnant 6. Contraindications to MR imaging 7. Tests positive for cannabis, illegal substances, or prescription medications without valid prescription 8. Currently taking steroids, opioids, or other agents that might affect brain circuitry per research team discretion 9. Use of cigarettes or other nicotine products within 12 hours of imaging visit 10. Use of stimulants within 24 hours of imaging visit 11. Presents an immediate danger to self or others as judged by research psychiatrist 12. Has had changes in medications within 30 days 13. Contribution of any co-occurring psychiatric comorbidity disproportionate to contribution of BDI or BDII 14. Meets DSM-5 criteria for current borderline or antisocial personality disorder 15. Meets DSM-5 criteria for alcohol and/or drug use disorder within 6 months, excluding caffeine and/or nicotine

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Magnetic Resonance Imaging
Imaging data for research purposes (high-resolution T1 structural and DWI MRI) will be acquired
Psychiatric testing
Subjects will be evaluated using psychiatric assessments
Eye-Tracking
Eye-tracking assessments will be done to biases toward positive and negative stimuli including images of neutral, fearful/threatening, sad, and happy.
Neuropsychology Evaluation
The neuropsychology evaluation will measure verbal learning/memory, attention/working memory, psychomotor speed, verbal fluency/processing speed, and executive function

Locations

Country Name City State
United States University Hospitals Cleveland Medical Center Cleveland Ohio

Sponsors (3)

Lead Sponsor Collaborator
Jennifer Sweet National Institute of Mental Health (NIMH), University Hospitals Cleveland Medical Center

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Characterize white matter (WM) connectivity with DWT to identify an anatomical substrate for BD that has future potential as a therapeutic target The imaging visit will consist of an MRI with diffusion-weighted imaging (DWI) sequences Day 1
See also
  Status Clinical Trial Phase
Completed NCT05111548 - Brain Stimulation and Cognitive Training - Efficacy N/A
Completed NCT02855762 - Targeting the Microbiome to Improve Clinical Outcomes in Bipolar Disorder N/A
Recruiting NCT05915013 - Alpha-Amino-3-Hydroxy-5-Methyl-4- Isoxazole Propionic Acid Receptor Components of the Anti-Depressant Ketamine Response Phase 1
Recruiting NCT05206747 - Ottawa Sunglasses at Night for Mania Study N/A
Completed NCT02513654 - Pharmacokinetics, Safety and Tolerability of Repeat Dosing Lamotrigine in Healthy Chinese Subjects Phase 1
Recruiting NCT06313918 - Exercise Therapy in Mental Disorders-study N/A
Completed NCT02304432 - Targeting a Genetic Mutation in Glycine Metabolism With D-cycloserine Early Phase 1
Recruiting NCT06197048 - Effect of Nutritional Counseling on Anthropometry and Biomarkers in Patients Diagnosed With Schizophrenia/Psychosis or Bipolar Affective Disorder N/A
Completed NCT03497663 - VIA Family - Family Based Early Intervention Versus Treatment as Usual N/A
Completed NCT04284813 - Families With Substance Use and Psychosis: A Pilot Study N/A
Completed NCT02212041 - Electronic Cigarettes in Smokers With Mental Illness N/A
Recruiting NCT05030272 - Comparing Two Behavioral Approaches to Quitting Smoking in Mental Health Settings N/A
Recruiting NCT04298450 - ED to EPI: Using SMS to Improve the Transition From the Emergency Department to Early Psychosis Intervention N/A
Active, not recruiting NCT03641300 - Efficacy of Convulsive Therapies for Bipolar Depression N/A
Not yet recruiting NCT04432116 - Time and Virtual Reality in Schizophrenia and Bipolar Disorder N/A
Completed NCT02970721 - Use of Psychotropic Medications Among Pregnant Women With Bipolar Disorder
Terminated NCT02893371 - Longitudinal Comparative Effectiveness of Bipolar Disorder Therapies
Terminated NCT02909504 - Gao NARASD Lithium Study Phase 4
Recruiting NCT02481245 - BezafibrateTreatment for Bipolar Depression: A Proof of Concept Study Phase 2
Recruiting NCT03088657 - Design and Methods of the Mood Disorder Cohort Research Consortium (MDCRC) Study